throbber
Sender:
`
`Dumaswala, Ashwini </O=CARTER-W ALLACE/OU=EXCHANGE
`ADMINISTRATIVE GROUP
`(FYDIBOHF23 SPDL T)/CN=RECIPIENTS/CN=ASUMASW ALA>
`Sent:
`Wednesday, November 2, 2011 3:40:52 PM
`Recipient:
`Roecklein, Bryan <Bryan.Roecklein@meda.us>
`Subject:
`RE: ET Dymista presentation
`Attachments: 2012 Dymista Strat Plan for ET Final.pptx
`
`Hello Bryan,
`
`Please see the attached.
`
`Thank you,
`
`Ashwini
`
`From: Roecklein, Bryan
`Sent: Wednesday, November 02, 2011 11:25 AM
`To: Dumaswala, Ashwini
`Subject: ET Dymista presentation
`
`Ashwini, can you send me an electronic copy of your slides.
`
`Thanks, Bryan
`
`Bryan Roecklein, Ph.D.
`Vice President, Marketing and Business Development
`Meda Pharmaceuticals
`Somerset NJ, 08873
`Office: 732-564-2366
`
`PLAINTIFFS'
`TRIAL EXHIBIT
`PTX1118 e
`
`xhibitsticker.com
`
`MEDA_APTX0177 4595
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PTX1118-00001
`
`1
`
`CIP2064
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`

`

`2(]~12 DYMISTA Strategic Plan
`
`Pnesented: October 28, 2011
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX0177 4596
`
`PTX1118-00002
`
`2
`
`

`

`Today's objectives
`
`• Present the Dymista 2012 Strategic Plan
`
`• Gain ET alignment
`
`• De~termine action steps to answer any outstanding questions
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`2
`
`PIED A
`
`MEDA_APTX0177 4597
`
`PTX1118-00003
`
`3
`
`

`

`xecutive Summary
`
`Establish Dymistat as the
`branded TRx and sales
`leader in SAR
`
`2012 Financials:
`• TRx: 448K
`• Net sales: $33.1 MM
`• EBITDA: ($36MM)
`• Gross/net%: 61.5%
`
`2012 Commercial
`SUQ.Qort:
`
`• Personal & Nonpersonal
`Promotion
`• KOL initiatives
`• Managed Care
`• Public Relations
`• CRM/Digital
`
`----·Goals
`• Take share from other prescription SAR products (specifically,
`intranasal steroids and intranasal steroid/anthistamine combinations)
`
`• Achieve 4.5% share of the nasal spray market by the end of 2013
`
`• Deliver positive cash flow by the end of 2013 and Net Sales of $199
`million (with 375 sales force expansion in 2013)
`
`Key Strategies:
`
`•
`
`•
`
`•
`
`Ensure access to Dymista by eliminating 1managed care
`and trade barriers
`
`Drive early trial and repeat use of Dymista via successful
`first experience
`
`Maxirnize exposure of Dymista and drive efficiencies
`across communication touchpoints
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX0177 4598
`
`PTX1118-00004
`
`4
`
`

`

`Where we are today:: Product churn
`
`I Patient tries 2nd OTC
`
`I
`
`First Rx: Patient goes to
`Dr. and receiv~es INS (in
`addition to their OTC)
`and/or Xyzal neplaces
`their OTC
`
`Second Rx: Patient returns to
`Dr. and receives Singulair or
`patie~nt goes to allergist and
`receives IN~+ INAH
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`Third Rx: Patient
`returns to Dr. and
`gets INS+ INAH
`flED"
`
`MEDA_APTX0177 4599
`
`PTX1118-00005
`
`5
`
`

`

`Where we are today:: The current situation
`
`1. HCPs recognize that while products in their current armamentarium treat the
`symptoms of SAR, their patients are not receiving "complete relief"
`
`• Patients and physicians often "churn" through several OTC and Rx products
`
`• Generic fluticasone is the "easy-·to-Rx" product when oral antihistarr1ines alone are
`not enough
`
`• There is a disconnect between HCP perception of SAR symptorns and patient
`perception
`
`2. INS + INJ~H therapy is the 2nd or 3rd Rx in the current treatment algorithm (mild
`patients are treated with OTCs)
`
`• The natural HCP positioning for INS + INAH therapy is for moderate to severe
`patients
`
`• Positive patient feedback is key to changing the algorithm and establishing a new
`standard of care
`
`• To date, there has been little ne·w news in the INS or INAH category to change the
`ft£i)£1 5
`algorithn1
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX0177 4600
`
`PTX1118-00006
`
`6
`
`

`

`Where we are today:: The current situation
`
`3. Impact of managed care and cost continue to be the main concern of HCPs
`
`• Patient out-of-pocket cost is an increasingly important decision critenion in
`prescribing decisions,
`
`• Obstacles at point of purchase vvould significantly impact prescriptions
`• Any payor restrictions would significantly impact prescriptions and will drive
`ne~1ative feedback
`• Unless there is meaningful product differentiation, HCPs Rx the product that
`is e,asiest, not always best
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIEDAs
`
`MEDA_APTX01774601
`
`PTX1118-00007
`
`7
`
`

`

`The overall Rhinitis market is flat; The nasal steroid market is growing 5°/o
`per year, increasing the opportunity for Dymista; Growth is bein~J driven by
`fluticasone~
`
`Millions of TRx
`90
`80
`70
`
`60
`
`50
`
`40
`
`30
`
`20
`
`10
`
`0
`
`MAT 9/2008
`
`MAT 9/2009
`
`MAT 9/2010
`
`MAT 9/2011
`
`W&..'tm Nasal Antihistamine
`=~=l=~=~=~~=~=~; Oral Antihistamine
`lllllilllllllliNS
`,.._,Rhinitis
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`7
`
`PIED A
`
`MEDA_APTX0177 4602
`
`PTX1118-00008
`
`8
`
`

`

`D~tmista ChallengE3S & Opportunities
`
`Challenges
`
`Opportunities
`
`• Current treatment algorithm places INS +
`I NAH therapy 2 or 3rd Rx
`
`• There is a significant unmet need in the
`treatment of SAR
`
`• SAR is considered a nuisance condition by
`HCPs
`
`• Robust head-to-head clinical data for additional
`data mining (N=4633)
`
`• Lack of supportive data for INS+INAH combo
`• vs. oral antihistamines
`• vs. single entities used in combination
`• Pharmacoeconomic data
`
`• Efficacy superior to market leader
`
`• Rapid onset of action and more complete
`symptom relief vs. single entity therapies
`
`• Managed care supports low cost generics as
`the "easy-to-Rx" product and supports allergy
`treatment guidelines
`
`• First combination spray
`
`• Meda Allergy expertise
`
`• Limited Meda sales force reach
`
`• Branded market leaders leaving space
`
`• Limited KOL advocacy
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`8
`
`MEDA_APTX0177 4603
`
`PTX1118-00009
`
`9
`
`

`

`Dymista Marketing Strategy
`
`~~
`
`Churning
`
`• INS+ INAH are
`2nd or 3rd Rx
`• SARis a
`nuisance
`condition
`• No product
`provides
`complete relief
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`More complete
`relief
`
`• Success with
`the first
`prescription
`
`• Fast and more
`complete relief
`
`• Patient
`satisfaction
`
`PIED A
`
`MEDA_APTX0177 4604
`
`PTX1118-00010
`
`10
`
`

`

`Dyn1ista is the seasonal allergic rhinitis solution
`
`HCP NEEDS
`
`SOLUTION
`
`Product that provides fast
`and more complete
`symptom rE~Iief the first
`time
`
`I Product that is easy to Rx
`
`Product that makes
`patients happy
`
`Dymista provides-rapid and nnore complete
`symptom relief-that HCPs & patients can rely on
`
`Dymista is the first and only prescription
`medication to combine the effective anti(cid:173)
`inflammatory relief of a corticosteroid coupled with
`the rapid multi-symptom relief of a nasal
`antihistamine
`
`So that: patients can have fast, superior symptom
`control in a single spray
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`10
`
`PIED A
`
`MEDA_APTX0177 4605
`
`PTX1118-00011
`
`11
`
`

`

`Dyn1ista Growth in TRx with the 375 rep expansion
`
`375 reps
`+10% !)rowth
`2.8MM TRx
`
`··············································+
`
`375 reps
`+475% growth
`2.5MM TRx
`
`.-. 3,000
`tn
`"C
`
`s::::: = :2,500
`
`:::l
`0
`~ :2,000
`._.
`~
`1- 1,500
`
`6/2011 Launch
`200 reps
`448K TRx
`
`~
`
`1,000
`
`500
`
`0
`
`2012
`
`2013
`
`2014
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`11
`
`PIED A
`
`MEDA_APTX0177 4606
`
`PTX1118-00012
`
`12
`
`

`

`Launch success is based upon a strong foundcition
`
`en
`><
`0:::
`I-
`
`Medical/
`KOL
`
`Push Through
`
`Sales
`
`Pull Through
`
`Trade
`
`Distribution
`
`1\/lanaged Care
`
`Access
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`12
`
`PIED A
`
`MEDA_APTX0177 4607
`
`PTX1118-00013
`
`13
`
`

`

`Managed <~are: Situation A.nalysis
`
`• Astepro 0.15o/o covered on 2nd tier on the majority of plans as a result of line
`extension strategy and high rebates (35-40°/o)
`
`•
`
`2nd tier status for Astepro 0.15o/o has had minimal impact on market share gains
`
`• Rhinitis nnarket has shifted to OTC (Orals) and generic Rx in recent years decreasing
`the size of the category
`- Historically, MHC payers relied upon Tiered copays to manage the category
`- Currently, MHC would prefer not to actively manage the category any more than
`they do now
`
`• Net cost of new branded entrants will be compared to the overall net cost of currently
`available products
`- Convenience is not a reason to demand higher price
`- Solid outcomes or pharmacoeconomic rationale is key
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX0177 4608
`
`PTX1118-00014
`
`14
`
`

`

`Managed Care Driving Principle: Maximize Profitability
`
`Without rebates, Dymista coverage is at risk however rebates similar to P\stepro 0.15o/a will
`impact profitability
`
`Example:
`
`W.AC
`A\JVP
`
`Dymista
`$120
`$150
`
`Astepro 0.15o/a
`$104
`$130
`
`A\JVP-17o/o
`Co pay
`Cost to plan
`Rebates
`Net cost to plan
`
`$124
`$ 50
`$ 74
`
`$ 74
`
`$108
`$ 25
`$ 83
`$ 36
`$ 47
`
`*Rebating (35%) to achieve Tier 2 status for Astepro; Assumes Tier 3 coverage for Dymista
`
`Hybrid Strate~~y
`•
`Unrestricted Tier 3 access on plans where we do not currently offer heavy rebates
`•
`On plans ·where we do, we would offer a 22% rebate to achieve unrestricted Tier 3 access
`•
`On the 4-~5 top national plans, rebate to get 2nd tier coverage
`•
`Note: Strategy will be confirmed through ZS research
`14
`
`PIED A
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX0177 4609
`
`PTX1118-00015
`
`15
`
`

`

`Pricing options and recommendation (Pro/Con anc~lysis)
`
`$120 WAC - Increase Astepro 0.15% in January and again in June to minimize the disparity in pricing
`between Dymista and Astepro 0.15% (+1 ~i% premium to Astepro 0.15%)
`
`-
`
`Pro's: With little price disparity between the two brands, a line extension strategy could be
`employed that avoids a full P&T Review. Access expected to be similar to Astepro 0.15%.
`
`- Con's: Rebates would be 35%-40% at launch affecting gross to net similar to Astepro 0.15%
`now (41.6% overall G2N)
`
`$114 WAC - Increase Astepro 0.15% in January and again in June to minimize the disparity in pricing
`between Dymista and Astpero 0.15%. Increase Dymista by 5% in January 2013 prior to spring allergy.
`(+15%/1 0% premium to Astepro 0.15%)
`
`-
`
`Pro's: Line Extension strategy easier to employ with little difference in cost between Dymista
`and Astepro 0.15%
`
`- Con's: Lost revenue of 5% from launch in 2012 to start of 2013
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX01774610
`
`PTX1118-00016
`
`16
`
`

`

`Ne:xt steps for Mana!~ed Care
`
`• Strategy & Pricing Finalization (Nov 2011)
`• ZS to validate strategy and co-pay acceptability
`• Estimate on tier status for Dymista by plan
`
`• P&L impact of hybrid approach (Dec 2011)
`
`• Pharmacoeconomic Data Conclusions (Dec 2011)
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`16
`
`PIED A
`
`MEDA_APTX01774611
`
`PTX1118-00017
`
`17
`
`

`

`Executive Summary: Tnade
`
`• Will leverage previous success in Trade with Astepro 0.1 o/o and Astepro 0.15o/o
`
`• Anticipate similar launch deal ten11s for Dymista as we did for Astepro 0.15%
`-
`7.5~:, off invoice, 7.5% distribution allowance, 60 days additional dating
`
`• Retail will want to see our promotional efforts behind the product (Sales Reps, DTC,
`etc.) and understand managed care formulary status
`
`• We will need to differentiate Dymista by partnering with pharmacies to ensure patient
`access to Dymista
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX01774612
`
`PTX1118-00018
`
`18
`
`

`

`Trade Olbjective I Strate~lY
`
`• Objective:
`- Attain stocking better than Astepro 0.15% (approx 30,000 retail outlets) while
`limiting excess inventory in vvarehouses at a discount
`
`- Develop Advocacy with key stakeholders in differentiating standard of care
`treatment
`
`• Strategy:
`-
`Leverage Meda best practice in launching both Astepro 0.1% and Astepro 0.15o/a.
`
`- Differentiate Dymista from other SAR products by partnering with the retail
`pharmacies to remove barriers and leverage opportunities
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX01774613
`
`PTX1118-00019
`
`19
`
`

`

`Ne:xt steps for Trade
`
`• Meet ·with key pharmacy chains to understand partnership opportunities (Nov/Dec)
`
`• Develop tactical plan to reach pharmacists (Nov/Dec)
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`19
`
`PIED A
`
`MEDA_APTX01774614
`
`PTX1118-00020
`
`20
`
`

`

`Salles: Situation Anctlysis
`
`• There are fewer competitive details in the SAR space
`• Anti1histamine details from l'v~erck and sanofi-aventis (main competitors are
`OTC and generics) have declined vs. PY
`
`• To date there has been limited new noise in the SAR space however 2 new branded
`entries are expected by 2013 (leva and Sunovian)
`
`• Meda sales force will be realigned to Dymista targets as of Jan 2012 however there
`is still a need to optimize sales force size
`
`•
`
`In 2012, there will be a gap between approval of Dymista and when product is
`available
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`20
`
`PIED A
`
`MEDA_APTX01774615
`
`PTX1118-00021
`
`21
`
`

`

`Sales Guiiding Principle: !Launch with Excellence
`
`•
`
`LAUNCH: \Nith 200 rep sales force
`- Realign from current 80/120 structure effective January 2012
`-
`Territories optimized geographically for Dymista; Targets optimized for Astepro 0.15%>
`until 1 month prior to launch
`Training: assign 2 training managers to Dymista (add headcount for an additional
`trainin~~ manager)
`
`-
`
`• EXECUTE: Plans with excellence
`- Measure performance against re~ach, frequency and sample targets
`- Structure IC plan to support execution (Astepro 0.15°/o until Dymista launch)
`
`• EXPAND: Effective January 2013
`- Recruitment & training beginnin~l in Fall 2012
`- Consider utilizing outside resources for recruitment and interviewing so as to minimize
`field management disruption during the Fall allergy season
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX01774616
`
`PTX1118-00022
`
`22
`
`

`

`Expansion
`
`Assumptions
`•
`Incremental 175 representatives
`• Fully trained and integrated into sales force so that impactful selling
`occurs during 2013 Spring allergy season
`Timing
`• Complete sales force ali!~nment analysis by August 1l 2012
`1\/lanagement team selections completed by Sept. 1l 2012
`•
`• Begin representative interviewing Sept. 2012
`()n-board the week of Oct. 29l 2012
`•
`•
`2 month training progran1
`1\Jew alignment effective January 1l 2013
`•
`- December 2012- new alignment POA meetings
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX01774617
`
`PTX1118-00023
`
`23
`
`

`

`Expansion
`
`Resources
`• Outside services
`-
`Identifying, contacting, and managing the recruiting process
`- Building the interview process, identifying teams, and provide any additional
`training around the procBss
`- Contracting for interview site services and managing the logistics of
`scheduling, travel, hotels, meals, etc.
`- Being on the interview sites as interviewers and managing thle sites
`-
`()n-boarding support (i.e. offer letters, reference checks, background
`checks, etc.)
`- Training support
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX01774618
`
`PTX1118-00024
`
`24
`
`

`

`Risk of not starting n3cruitment in 2012
`
`• Sales not maximized for 2013 spring allergy season
`
`• P&~L at risk and suboptirnal growth trajectory
`
`• De!crease in share of voice in an environment with increased noise
`(Teva and Sunovian launches)
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`24
`
`PIED A
`
`MEDA_APTX01774619
`
`PTX1118-00025
`
`25
`
`

`

`ExE3cutive Summary: Medical Marketing
`
`• Objectives
`-
`Leverage KOLs to establish Dymista as the standard of care
`- Provide avenues to discuss product development and remove any obstacles to
`early trial and repeat use of Dymista
`- Build credible, evidence-based platform to be communicated for Dymista,
`surrounding 2012 launch and into 2013
`
`• Strategy
`
`- Disseminate our clinical and economic data to build a body of knowledge for the
`use of Dymista and establish as a standard of care
`
`- Discuss through case based learning and real world experience the benefits of
`Dymista to drive trial and repeat use as well as maximize exposure
`
`- Displace churn by exchanging inferior product offerings with Dyrnista
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX01774620
`
`PTX1118-00026
`
`26
`
`

`

`Dymista Gioal: Deliver $33MrVI NR by the end of 2012
`
`201 ~! Forecast & P&L )~ssumptions
`• Supply available and trade stocked for launch in June 2012
`• 200 reps at launch
`• VVAC $120/Rx
`• 5 1o/o Nasal market growth (driven by fluticasone)
`• Liimited restrictions frorn Managed Care
`• 61.5°/o Gross to Net
`• EBITDA reflects launch investment
`-- Trade unit cost at 16o/o of NR
`-- Sample unit cost at $4 and $6
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`26
`
`MEDA_APTX01774621
`
`PTX1118-00027
`
`27
`
`

`

`2012 P&L
`
`Sales force size
`*Note: 2012 assumes a June launch
`2012 includes the cost of DTC exploration and sales force recruitment for +175 reps
`PDEs calculated based upon a 3 product detail
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX01774622
`
`PTX1118-00028
`
`28
`
`

`

`Revised C:ontract Having A Large Impact on Sample <~osts
`And P&L
`
`475%
`
`503%
`
`247%
`
`150%
`
`$1.5MM
`
`$3.6MM
`
`($26.5MIV1)
`
`($36.0MM)
`
`Revised Contract
`• Trade Units increased from $3.25/unit to 16% of Net sales
`
`• Sample unit costs increased from $2 to $4 & $6
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX01774623
`
`PTX1118-00029
`
`29
`
`

`

`Critical Success Metrics
`
`J
`J
`J
`
`J
`
`Provided unrestricted access to >80% of patient lives
`
`Gain distribution at >30,000 pharmacies
`
`Shipments & Daily Net Sales per plan
`
`NRx & TRx per plan
`
`Coupon redemption at launch> Astepro
`
`50% awareness 6 months post launch among HV
`Targets; Aided awareness +80% post launch
`
`Sales force achievement against reach, frequency and
`sam pie tatrgets
`
`Deliver targeted reach and lift via speaker programs
`
`Achieve ROI ~ benchmark for nan personal promotion
`tactic
`
`J
`J
`J
`J
`J
`
`J
`
`J
`J
`J
`J
`J
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`29
`
`PIED A
`
`MEDA_APTX01774624
`
`PTX1118-00030
`
`30
`
`

`

`IMrVIEDIATE NEXT ~3TEPS
`
`• El- Brand Plan Alignrnent (Oct 28th, 2011)
`• ZE> Forecast Validation (Oct 31st, 2011)
`• Supply Dates Confirrned (Oct 31 5t, 2011)
`• Final Positioning (Oct 31st, 2011)
`• Final Managed Care ~Strategy & Pricing (Nov. 20111)
`• Final Creative Concept (Dec. 2011)
`• Final inputs for Dymista Target List (Dec. 2011)
`• Final date for launch rneeting (Nov. 2011)
`• Budget approved by ~)wed en (Dec. 2011)
`
`• Reinstitute Bi-Monthly Steering Committee Updates
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`30
`
`PIED A
`
`MEDA_APTX01774625
`
`PTX1118-00031
`
`31
`
`

`

`In C)rder to be successful we need to ...
`
`Continue the strong inte~Jration across cross functional teams
`
`Stay focused against the strategies
`
`Comrnunicate a consistent single-minded message
`
`Maintain communication between the US and Global
`
`Differentiate ourselves internally and externally
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`31
`
`PIED A
`
`MEDA_APTX01774626
`
`PTX1118-00032
`
`32
`
`

`

`SUBJECTTO
`STIPULATED
`PROTECTIVE
`ORDER
`
`< m
`0
`:;o
`c m
`:;o
`
`cn:::r: c(cid:173)mG>
`c.... I mr
`o-<
`-I(')
`-10 oz
`en!!
`-IC
`-m
`""'z
`c-1
`r (cid:173)
`)>)>
`- l r m•
`c
`"'tJ
`:;o
`0
`-I m
`(')
`-I
`
`HIGHLY
`CONFIDENTIAL-
`
`Appendix
`
`32
`
`3
`PI
`tl
`D
`
`MEDA_APTX01774627
`
`33
`
`PTX1118-00033
`
`PTX1118-00033
`
`33
`
`
`
`

`

`IN~) are fueling the ~~x market stability ...
`
`Without INS, the market ,would have declined 8.4°/o with J~llegra OTC
`Millions of TRx
`4.0
`
`3.5
`
`3.0
`
`2.5
`
`2.0
`
`1.5
`
`1.0
`
`0.5
`
`0.0
`
`10
`-ii-2011
`
`.Jan
`
`February
`
`March
`
`April
`
`May
`
`June
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`33
`
`PIED A
`
`MEDA_APTX01774628
`
`PTX1118-00034
`
`34
`
`

`

`Slide 33
`
`BR34
`
`What am I looking at here? Y axis is what? Total Rx's in category?
`
`From the graphs I don't see what supports the statements.
`
`what I see is a decline of X percent from 2010 to 2011 of Rx of something.
`
`Bryan Roecklein, 10/23/2011
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX01774629
`
`PTX1118-00035
`
`35
`
`

`

`Growth in the INS market is being driven by fluticasone IBR:3~
`
`"II ions of TRx
`
`.5
`
`.0
`
`.... / ···· Fluticasone/Fionase
`
`-§-NASON EX
`
`NASACORT AQ
`~RHINOCORT AQUA
`VERAMYST
`-e-OMNARIS
`TOTAL INS
`
`~~~~~~~~~~~~~~~~~~~~~~~~~
`~~~~~~~~~~~~~~~~~~~~~~~~~
`~~~~~~~~~~~~~~~~~~~~~~~~~
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`34
`
`PIED A
`
`MEDA_APTX0177 4630
`
`PTX1118-00036
`
`36
`
`

`

`Slide 34
`
`BR35
`
`Since you have total in the previous slide (I believe), I'd eliminate here and you'll see the dynamic for fluticasone and Nasonex better.
`Bryan Roecklein, 10/23/2011
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX01774631
`
`PTX1118-00037
`
`37
`
`

`

`P&L
`
`448K
`TRx
`$53.8MM
`Gross Sales
`$33.1MM
`Net Sales
`$ 9.0MM
`Sample Cost
`$30.0MM
`A&P
`($36.0MM)
`EBITDA
`154K
`PDEs
`200
`Sales force size
`*Note: 2012 assumes a June launch
`**2013 Does not include DTC
`PDEs calculated based upon a 3 product detail
`
`2,578K
`$324.7MM
`$199.6.0MM
`$41.2MM
`$40.0MM**
`$39.9MM
`495K
`375
`
`47E) 0/o
`
`50~~%
`
`50~~%
`
`358°/o
`
`33~/o
`NA
`221%
`
`87~/o
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX0177 4632
`
`PTX1118-00038
`
`38
`
`

`

`&P Breakdovvn
`
`R~emember to
`print out full
`sheet
`
`Samples
`
`Selling materials
`
`Sales Force Expansion
`
`Other promotion
`
`E-Business
`
`DTC Evaluation and Development
`
`Direct Mail
`
`Managed Care/Trade
`
`MLB/KOL/Field Funds
`
`Lunch & Learn
`
`DTP/Patient Ed
`
`Public Relations
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`PIED A
`
`MEDA_APTX0177 4633
`
`PTX1118-00039
`
`39
`
`

`

`Dyn1ista Growth in TRx with a 200 rep sales force
`
`200 reps
`+371% growth
`2.1MM TRx
`
`200 reps
`+10% growth
`2.3MM TRx
`
`+
`
`6/2011 Launch
`200 reps
`448KTRx
`
`Dymista
`
`.-.2,500
`tn
`"C
`s::::: ns
`~ 2,000
`0
`.c:
`1-
`-; 1,500
`0:::
`1-
`
`1,000
`
`500
`
`0
`
`2012
`
`2013
`
`2014
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`37
`
`PIED A
`
`MEDA_APTX0177 4634
`
`PTX1118-00040
`
`40
`
`

`

`Ne1W Competitive Product Entries
`
`Sunovian - ciclesonide ~iF A nasal inhaler- NDA filed 6/2011
`
`Teva- beclomethasone dipropionate hydrofluoroalkane (BDH)
`nasal HFA- NDA filed 8/2011
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`38
`
`PIED A
`
`MEDA_APTX0177 4635
`
`PTX1118-00041
`
`41
`
`

`

`SUBJECTTO
`STIPULATED
`PROTECTIVE
`ORDER
`
`HIGHLY
`CONFIDENTIAL-
`
`cn:::r:
`c,... m \II
`c.... I mr
`o-<
`-I(')
`-10 oz
`en!!
`-IC
`""'m cz
`r-1
`)>(cid:173)
`-I)>
`m':'""
`c
`"'tJ
`:;o
`0
`-I m
`(')
`-I
`< m
`0
`:;o
`c m
`:;o
`
`
`
`3
`PI
`tl
`D
`
`MEDA_APTX01774636
`
`42
`
`PTX1118-00042
`
`PTX1118-00042
`
`42
`
`
`

`

`Peak azelastine franchis~e sales - MAT 2/2008 - 3.28MM TRx
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`40
`
`PIED A
`
`MEDA_APTX01774637
`
`PTX1118-00043
`
`43
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket